M. Hung

Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer.

G. Hortobagyi, M. Hung, N. Ueno, 2000, Advances in experimental medicine and biology.

CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.

Jia Fan, Jian Zhou, Yongsheng Xiao, 2024, Journal of hepatology.

Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma

Chunxiao Liu, Yufan Qiu, W. Xia, 2024, Nature communications.

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

M. Konopleva, Heng-Huan Lee, J. Hsu, 2023, Journal for ImmunoTherapy of Cancer.